Ionis Pharmaceuticals, Inc. (LON: 0JDI)
London
· Delayed Price · Currency is GBP · Price in USD
32.98
+0.27 (0.83%)
Jan 23, 2025, 2:42 PM BST
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $133.81M USD in the quarter ending September 30, 2024, a decrease of -7.21%. This brings the company's revenue in the last twelve months to $803.07M, up 30.57% year-over-year. In the year 2023, Ionis Pharmaceuticals had annual revenue of $787.65M with 34.10% growth.
Revenue (ttm)
$803.07M
Revenue Growth
+30.57%
P/S Ratio
n/a
Revenue / Employee
$866.31K
Employees
927
Market Cap
4.17B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Ionis Pharmaceuticals News
- 8 days ago - Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034 - GlobeNewsWire
- 10 days ago - Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum - PRNewsWire
- 14 days ago - Ionis Pharmaceuticals to Present at J.P. Morgan Healthcare Conference - GuruFocus
- 14 days ago - Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 weeks ago - Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval - Seeking Alpha
- 4 weeks ago - FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood - Benzinga
- 4 weeks ago - FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood - Benzinga
- 4 weeks ago - TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet - PRNewsWire